{"entity":{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","aka":[],"tldr":"Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.","summary":"Jeremie Calais is Associate Professor and Director of the Clinical Research Program in the Ahmanson Translational Theranostics Division at UCLA, part of the UCLA Jonsson Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and radioligand therapy, he leads prospective PSMA PET and PSMA radioligand therapy trials, including the head-to-head comparison of PSMA PET with fluciclovine PET and dosimetry research. His papers include the Lancet Oncology comparative imaging trial of 18F-fluciclovine and 68Ga-PSMA-11 PET-CT in early biochemical recurrence after prostatectomy and the Journal of Nuclear Medicine RESIST-PC phase 2 trial of 177Lu-PSMA-617 in the UCLA cohort. His work centres on prostate cancer theranostics.","asOf":"2026-09-08","links":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":["psma"],"drugs":[],"companies":[],"institutions":["ucla-jonsson"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-nuclear-medicine"],"dependsOn":[],"notes":[],"role":"Associate Professor; Director, Clinical Research Program, Ahmanson Translational Theranostics Division, UCLA","institutionId":"ucla-jonsson","specialisms":["PSMA PET","Radioligand therapy","Clinical trials"],"profiles":[{"label":"UCLA profile","url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Jeremie%20Calais"}],"papers":[{"title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","journal":"Lancet Oncology","year":2019,"url":"https://doi.org/10.1016/s1470-2045(19)30415-2","doi":"10.1016/s1470-2045(19)30415-2"},{"title":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort","journal":"Journal of Nuclear Medicine","year":2021,"url":"https://doi.org/10.2967/jnumed.121.261982","doi":"10.2967/jnumed.121.261982"}]},"route":"/people/jeremie-calais/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"institution":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/"}],"journal":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/"}]}}